{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T11:27:00Z","timestamp":1790681220478,"version":"4.1.0"},"reference-count":74,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,3,24]],"date-time":"2023-03-24T00:00:00Z","timestamp":1679616000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Neurosarcodosis is one of the most frequent differential diagnoses of multiple sclerosis (MS) and requires central nervous system (CNS) biopsy to establish definite diagnosis according to the latest consensus diagnostic criteria. We here analyzed diagnostic values of basic cerebrospinal fluid (CSF) parameters to distinguish neurosarcoidosis from MS without CNS biopsy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We retrospectively assessed clinical, radiological and laboratory data of 27 patients with neurosarcoidosis treated at our center and compared following CSF parameters with those of 138 patients with relapsing-remitting MS: CSF white cell count (WCC), CSF\/serum albumin quotient (Q<jats:sub>alb<\/jats:sub>), intrathecal production of immunoglobulins including oligoclonal bands (OCB), MRZ reaction, defined as a polyspecific intrathecal production of IgG reactive against \u22652 of 3 the viruses measles (M), rubella (R), and zoster (Z) virus, and CSF lactate levels. Additional inflammatory biomarkers in serum and\/or CSF such as neopterin, soluble interleukin-2 receptor (sIL-2R) and C-reactive protein (CRP) were assessed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>There was no significant difference in the frequency of CSF pleocytosis, but a CSF WCC &amp;gt; 30\/\u03bcl was more frequent in patients with neurosarcoidosis. Compared to MS, patients with neurosarcoidosis showed more frequently an increased Q<jats:sub>alb<\/jats:sub> and CSF lactate levels as well as increased serum and CSF levels of sIL-2R, but a lower frequency of intrathecal IgG synthesis and positive MRZ reaction. Positive likelihood ratio (PLR) of single CSF parameters indicating neurosarcoidosis was highest, if (a) CSF WCC was &amp;gt;30\/\u03bcl (PLR 7.2), (b) Q<jats:sub>alb<\/jats:sub> was &amp;gt;10 \u00d7 10<jats:sup>\u22123<\/jats:sup> (PLR 66.4), (c) CSF-specific OCB were absent (PLR 11.5), (d) CSF lactate was elevated (PLR 23.0) or (e) sIL-2R was elevated (PLR&amp;gt;8.0). The combination of (a) one of three following basic CSF parameters, i.e., (a.1.) CSF WCC &amp;gt;30\/ul, or (a.2.) Q<jats:sub>Alb<\/jats:sub> &amp;gt;10 \u00d7 10<jats:sup>\u22123<\/jats:sup>, or (a.3.) absence of CSF-specific OCB, and (b) absence of positive MRZ reaction showed the best diagnostic accuracy (sensitivity and specificity each &amp;gt;92%; PLR 12.8 and NLR 0.08).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Combined evaluation of basic CSF parameters and MRZ reaction is powerful in differentiating neurosarcoidosis from MS, with moderate to severe pleocytosis and Q<jats:sub>Alb<\/jats:sub> elevation and absence of intrathecal IgG synthesis as useful rule-in parameters and positive MRZ reaction as a rule-out parameter for neurosarcoidosis.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneur.2023.1135392","type":"journal-article","created":{"date-parts":[[2023,3,24]],"date-time":"2023-03-24T05:58:58Z","timestamp":1679637538000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":17,"title":["Differentiating neurosarcoidosis from multiple sclerosis using combined analysis of basic CSF parameters and MRZ reaction"],"prefix":"10.3389","volume":"14","author":[{"given":"Benjamin","family":"Vlad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Neidhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Hilty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Ziegler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilijas","family":"Jelcic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,3,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1001\/archneur.60.8.1166","article-title":"Neurosarcoidosis","volume":"60","author":"Burns","year":"2003","journal-title":"Arch Neurol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1136\/jnnp.2007.124263","article-title":"Sarcoidosis of the nervous system","volume":"7","author":"Joseph","year":"2007","journal-title":"Pract Neurol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1183\/13993003.00477-2016","article-title":"Sarcoidosis incidence and prevalence: a nationwide register-based assessment in Sweden","volume":"48","author":"Arkema","year":"2016","journal-title":"Eur Respir J."},{"key":"B4","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.2147\/NDT.S143180","article-title":"Epidemiology and costs of multiple sclerosis in Switzerland: an analysis of health-care claims data, 2011\u20132015","volume":"13","author":"Blozik","year":"2017","journal-title":"Neuropsychiatr Dis Treat."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1177\/1352458520970841","article-title":"Rising prevalence of multiple sclerosis worldwide: insights from the Atlas of MS, third edition","volume":"26","author":"Walton","year":"2020","journal-title":"Mult Scler."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1212\/WNL.0000000000000273","article-title":"CNS inflammation other than multiple sclerosis: how likely is diagnosis?","volume":"82","author":"Street","year":"2014","journal-title":"Neurology."},{"key":"B7","doi-asserted-by":"publisher","first-page":"e2265","DOI":"10.1212\/WNL.0000000000006645","article-title":"Nationwide prevalence and incidence study of neuromyelitis optica spectrum disorder in Denmark","volume":"91","author":"Papp","year":"2018","journal-title":"Neurology."},{"key":"B8","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.msard.2019.06.002","article-title":"Incidence of pediatric neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody-associated disease in Denmark 2008\u20132018: a nationwide, population-based cohort study","volume":"33","author":"Boesen","year":"2019","journal-title":"Mult Scler Relat Disord."},{"key":"B9","doi-asserted-by":"publisher","first-page":"501","DOI":"10.3389\/fneur.2020.00501","article-title":"Epidemiology of neuromyelitis optica spectrum disorder and its prevalence and incidence worldwide","volume":"11","author":"Hor","year":"2020","journal-title":"Front Neurol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1136\/jnnp-2020-323158","article-title":"Prevalence and incidence of neuromyelitis optica spectrum disorder, aquaporin-4 antibody-positive NMOSD and MOG antibody-positive disease in Oxfordshire, UK","volume":"91","author":"O'connell","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B11","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1212\/NXI.0000000000001084","article-title":"Neurosarcoidosis: pathophysiology, diagnosis, and treatment","author":"Bradshaw","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B12","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1378\/chest.130.3.855","article-title":"Comparison of sarcoidosis phenotypes among affected African-American siblings","volume":"130","author":"Judson","year":"2006","journal-title":"Chest."},{"key":"B13","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1164\/rccm.201204-0708OC","article-title":"A novel sarcoidosis risk locus for Europeans on chromosome 11q13.1","volume":"186","author":"Fischer","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1164\/rccm.201209-1582ED","article-title":"Genetic susceptibility to sarcoidosis, a chronic inflammatory disorder","volume":"186","author":"Van Moorsel","year":"2012","journal-title":"Am J Respir Crit Care Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.ccm.2015.08.002","article-title":"Genetics of Sarcoidosis","volume":"36","author":"Fingerlin","year":"2015","journal-title":"Clin Chest Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"S429","DOI":"10.1513\/AnnalsATS.201707-565OT","article-title":"Genetic, immunologic, and environmental basis of sarcoidosis","volume":"14","author":"Moller","year":"2017","journal-title":"Ann Am Thorac Soc."},{"key":"B17","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1159\/000477300","article-title":"Characteristics and long-term outcome of neurosarcoidosis: a population-based study from 1976\u20132013","volume":"48","author":"Ungprasert","year":"2017","journal-title":"Neuroepidemiology."},{"key":"B18","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1093\/qjmed\/92.2.103","article-title":"Central nervous system sarcoidosis-diagnosis and management","volume":"92","author":"Zajicek","year":"1999","journal-title":"QJM."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1001\/jamaneurol.2018.2295","article-title":"Definition and consensus diagnostic criteria for neurosarcoidosis: from the neurosarcoidosis consortium consensus group","volume":"75","author":"Stern","year":"2018","journal-title":"JAMA Neurol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"e2545","DOI":"10.1212\/WNL.0000000000009491","article-title":"Distinguishing neurosarcoidosis from multiple sclerosis based on CSF analysis: a retrospective study","volume":"94","author":"Arun","year":"2020","journal-title":"Neurology."},{"key":"B21","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1177\/135245859800400302","article-title":"Cerebrospinal fluid\u2013physiology, analysis and interpretation of protein patterns for diagnosis of neurological diseases","volume":"4","author":"Reiber","year":"1998","journal-title":"Mult Scler."},{"key":"B22","doi-asserted-by":"publisher","first-page":"539","DOI":"10.3851\/IMP3140","article-title":"Cerebrospinal fluid viral load and neopterin in HIV-positive patients with undetectable viraemia","volume":"22","author":"Motta","year":"2017","journal-title":"Antivir Ther"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1007\/s00415-010-5623-3","article-title":"Soluble CSF interleukin 2 receptor as indicator of neurosarcoidosis","volume":"257","author":"Petereit","year":"2010","journal-title":"J Neurol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.clinbiochem.2018.06.010","article-title":"Focus on increased serum angiotensin-converting enzyme level: from granulomatous diseases to genetic mutations","volume":"59","author":"Lopez-Sublet","year":"2018","journal-title":"Clin Biochem."},{"key":"B25","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1002\/(SICI)1098-2825(1998)12:3&lt;137::AID-JCLA2&gt;3.0.CO;2-6","article-title":"Development of a new microparticle-enhanced turbidimetric assay for C-reactive protein with superior features in analytical sensitivity and dynamic range","volume":"12","author":"Eda","year":"1998","journal-title":"J Clin Lab Anal."},{"key":"B26","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1515\/CCLM.2001.051","article-title":"Reporting cerebrospinal fluid data: knowledge base and interpretation software","volume":"15","author":"Reiber","year":"2004","journal-title":"EJIFCC."},{"key":"B27","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1136\/jnnp.57.8.897","article-title":"Cerebrospinal fluid in the diagnosis of multiple sclerosis: a consensus report","volume":"57","author":"Andersson","year":"1994","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B28","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1007\/BF00422934","article-title":"The diagnostic significance of antibody specificity indices in multiple sclerosis and herpes virus induced diseases of the nervous system","volume":"70","author":"Felgenhauer","year":"1992","journal-title":"Clin Investig."},{"key":"B29","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1136\/jnnp.2008.151977","article-title":"Neurosarcoidosis: a study of 30 new cases","volume":"80","author":"Joseph","year":"2009","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1007\/s00415-018-8928-2","article-title":"Sarcoidosis of the central nervous system: clinical features, imaging, and CSF results","volume":"265","author":"Kidd","year":"2018","journal-title":"J Neurol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1177\/135245859800400304","article-title":"The intrathecal, polyspecific and oligoclonal immune response in multiple sclerosis","volume":"4","author":"Reiber","year":"1998","journal-title":"Mult Scler."},{"key":"B32","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s12987-015-0024-8","article-title":"The intrathecal, polyspecific antiviral immune response in neurosarcoidosis, acute disseminated encephalomyelitis and autoimmune encephalitis compared to multiple sclerosis in a tertiary hospital cohort","volume":"12","author":"Hottenrott","year":"2015","journal-title":"Fluids Barriers CNS."},{"key":"B33","first-page":"587","volume":"88","author":"Graef","year":"1994","journal-title":"Z Arztl Fortbild (Jena)."},{"key":"B34","doi-asserted-by":"publisher","first-page":"e40431","DOI":"10.1371\/journal.pone.0040431","article-title":"Intrathecal, polyspecific antiviral immune response in oligoclonal band negative multiple sclerosis","volume":"7","author":"Brecht","year":"2012","journal-title":"PLoS ONE."},{"key":"B35","doi-asserted-by":"publisher","first-page":"577989","DOI":"10.1016\/j.jneuroim.2022.577989","article-title":"Sarcoidosis and obsessive-compulsive symptoms","volume":"373","author":"Endres","year":"2022","journal-title":"J Neuroimmunol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1136\/bmj.329.7458.168","article-title":"Diagnostic tests 4: likelihood ratios","volume":"329","author":"Deeks","year":"2004","journal-title":"BMJ."},{"key":"B37","doi-asserted-by":"publisher","first-page":"655262","DOI":"10.3389\/fimmu.2021.655262","article-title":"Likelihood ratio approach and clinical interpretation of laboratory tests","volume":"12","author":"Fierz","year":"2021","journal-title":"Front Immunol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1046\/j.1525-1497.2002.10750.x","article-title":"Simplifying likelihood ratios","volume":"17","author":"Mcgee","year":"2002","journal-title":"J Gen Intern Med."},{"key":"B39","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1097\/NRL.0b013e3181b287df","article-title":"Neurosarcoidosis mimicry of multiple sclerosis: clinical, laboratory, and imaging characteristics","volume":"16","author":"Scott","year":"2010","journal-title":"Neurologist."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1212\/WNL.15.12.1147","article-title":"Neurological manifestations of sarcoidosis","volume":"15","author":"Wiederholt","year":"1965","journal-title":"Neurology."},{"key":"B41","doi-asserted-by":"publisher","first-page":"336","DOI":"10.7326\/0003-4819-87-3-336","article-title":"Neurologic manifestations in sarcoidosis: review of the literature, with a report of 23 cases","volume":"87","author":"Delaney","year":"1977","journal-title":"Ann Intern Med."},{"key":"B42","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1001\/archneur.1985.04060080095022","article-title":"Sarcoidosis and its neurological manifestations","volume":"42","author":"Stern","year":"1985","journal-title":"Arch Neurol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/0022-510X(86)90066-3","article-title":"Cerebrospinal fluid lysozyme and beta 2-microglobulin in neurosarcoidosis","volume":"73","author":"Oksanen","year":"1986","journal-title":"J Neurol Sci."},{"key":"B44","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1097\/00005792-199009000-00001","article-title":"Neurosarcoidosis: signs, course and treatment in 35 confirmed cases","volume":"69","author":"Chapelon","year":"1990","journal-title":"Medicine."},{"key":"B45","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1093\/qjmed\/hcp042","article-title":"Presentations and outcomes of neurosarcoidosis: a study of 54 cases","volume":"102","author":"Pawate","year":"2009","journal-title":"QJM."},{"key":"B46","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1186\/s12883-016-0741-x","article-title":"Clinical features, treatment and outcome in neurosarcoidosis: systematic review and meta-analysis","volume":"16","author":"Fritz","year":"2016","journal-title":"BMC Neurol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"13735","DOI":"10.1038\/s41598-021-92967-6","article-title":"Clinical characterization and outcomes of 85 patients with neurosarcoidosis","volume":"11","author":"Ramos-Casals","year":"2021","journal-title":"Sci Rep."},{"key":"B48","doi-asserted-by":"publisher","first-page":"289","DOI":"10.2214\/ajr.182.2.1820289","article-title":"Imaging manifestations of neurosarcoidosis","volume":"182","author":"Smith","year":"2004","journal-title":"AJR Am J Roentgenol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1001\/archneur.64.5.691","article-title":"Aggressive therapy for neurosarcoidosis: long-term follow-up of 48 treated patients","volume":"64","author":"Scott","year":"2007","journal-title":"Arch Neurol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1097\/MAO.0000000000000501","article-title":"Cranial base manifestations of neurosarcoidosis: a review of 305 patients","volume":"36","author":"Carlson","year":"2015","journal-title":"Otol Neurotol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1212\/WNL.0000000000004644","article-title":"Infliximab for the treatment of CNS sarcoidosis: a multi-institutional series","volume":"89","author":"Gelfand","year":"2017","journal-title":"Neurology"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1001\/jamaneurol.2017.2492","article-title":"Association of prognostic factors and immunosuppressive treatment with long-term outcomes in neurosarcoidosis","volume":"74","author":"Joubert","year":"2017","journal-title":"JAMA Neurol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/S1474-4422(21)00095-8","article-title":"MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis","volume":"20","author":"Wattjes","year":"2021","journal-title":"Lancet Neurol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"577904","DOI":"10.1016\/j.jneuroim.2022.577904","article-title":"Distinguishing CNS neurosarcoidosis from multiple sclerosis and an approach to \u201coverlap\u201d cases","volume":"369","author":"Chan","year":"2022","journal-title":"J Neuroimmunol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1212\/CPJ.0000000000000629","article-title":"Multiple sclerosis and sarcoidosis: a case for coexistence","volume":"9","author":"Tyshkov","year":"2019","journal-title":"Neurol Clin Pract."},{"key":"B56","doi-asserted-by":"publisher","first-page":"117621","DOI":"10.1016\/j.jns.2021.117621","article-title":"Neurosarcoidosis mimicry of MS: clues from cases with CNS tissue diagnosis","volume":"429","author":"Scott","year":"2021","journal-title":"J Neurol Sci."},{"key":"B57","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1136\/pgmj.2008.067769","article-title":"Immune-mediated and chronic inflammatory disease in people with sarcoidosis: disease associations in a large UK database","volume":"85","author":"Rajoriya","year":"2009","journal-title":"Postgrad Med J."},{"key":"B58","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1212\/WNL.38.3.378","article-title":"Magnetic resonance imaging in central nervous system sarcoidosis","volume":"38","author":"Miller","year":"1988","journal-title":"Neurology."},{"key":"B59","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1001\/archneur.1989.00520390036012","article-title":"Cerebrospinal fluid immunoglobulin abnormalities in neurosarcoidosis","volume":"46","author":"Borucki","year":"1989","journal-title":"Arch Neurol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/0022-510X(90)90153-E","article-title":"Local synthesis of specific IgG in the cerebrospinal fluid of patients with neurosarcoidosis detected by antigen immunoblotting using Kveim material","volume":"99","author":"Mclean","year":"1990","journal-title":"J Neurol Sci."},{"key":"B61","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s00415-016-8360-4","article-title":"The MRZ reaction as a highly specific marker of multiple sclerosis: re-evaluation and structured review of the literature","volume":"264","author":"Jarius","year":"2017","journal-title":"J Neurol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1212\/NXI.0000000000000725","article-title":"Analysis of soluble interleukin-2 receptor as CSF biomarker for neurosarcoidosis","author":"Otto","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1007\/s00415-012-6429-2","article-title":"Diagnostic pitfalls: a case of neurosarcoidosis mimicking tuberculous meningitis","volume":"259","author":"Scheibe","year":"2012","journal-title":"J Neurol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1177\/1352458517717804","article-title":"CSF and clinical data are useful in differentiating CNS inflammatory demyelinating disease from CNS lymphoma","volume":"24","author":"Ikeguchi","year":"2018","journal-title":"Mult Scler."},{"key":"B65","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/0022-510X(92)90113-Y","article-title":"Significance of CSF total neopterin and biopterin in inflammatory neurological diseases","volume":"111","author":"Furukawa","year":"1992","journal-title":"J Neurol Sci."},{"key":"B66","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3390\/biom8030084","article-title":"YKL-40, soluble IL-2 receptor, angiotensin converting enzyme and C-reactive protein: comparison of markers of sarcoidosis activity","author":"Uysal","year":"2018","journal-title":"Biomolecules."},{"key":"B67","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.3389\/fimmu.2020.01443","article-title":"Biomarkers in the diagnosis and prognosis of sarcoidosis: current use and future prospects","volume":"11","author":"Kraaijvanger","year":"2020","journal-title":"Front Immunol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/BF00887815","article-title":"Measurement of immune markers in the serum and cerebrospinal fluid of multiple sclerosis patients during clinical remission","volume":"242","author":"Shaw","year":"1995","journal-title":"J Neurol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1212\/WNL.37.5.878","article-title":"Neurosarcoidosis: cerebrospinal fluid lymphocyte subpopulations","volume":"37","author":"Stern","year":"1987","journal-title":"Neurology."},{"key":"B70","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1007\/s00415-005-0043-5","article-title":"Neurosarcoidosis. Clinical description of 7 cases with a proposal for a new diagnostic strategy","volume":"253","author":"Marangoni","year":"2006","journal-title":"J Neurol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1111\/ene.13975","article-title":"The cerebrospinal fluid CD4\/CD8 ratio and interleukin-6 and\u221210 levels in neurosarcoidosis: a multicenter, pragmatic, comparative study","volume":"26","author":"Chazal","year":"2019","journal-title":"Eur J Neurol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1111\/ane.13297","article-title":"Cerebrospinal fluid CD4(+) \/CD8(+) ratio in diagnosing neurosarcoidosis","volume":"142","author":"Nordstrom","year":"2020","journal-title":"Acta Neurol Scand."},{"key":"B73","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1159\/000353863","article-title":"Diagnostic accuracy measures","volume":"36","author":"Eusebi","year":"2013","journal-title":"Cerebrovasc Dis."},{"key":"B74","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1007\/s11547-017-0829-4","article-title":"Abnormal cervical lymph nodes in multiple sclerosis: a preliminary ultrasound study","volume":"123","author":"Giuliano","year":"2018","journal-title":"Radiol Med."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2023.1135392\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,24]],"date-time":"2023-03-24T05:59:02Z","timestamp":1679637542000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2023.1135392\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,24]]},"references-count":74,"alternative-id":["10.3389\/fneur.2023.1135392"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2023.1135392","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,24]]},"article-number":"1135392"}}